HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will participate in an analyst-led fireside chat at 4:00 p.m. EST on Wednesday, December 2 at the Piper Jaffray 27th Annual Healthcare Conference.
